

Simon J Harrison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9362503/publications.pdf>

Version: 2024-02-01

167
papers

5,937
citations

81900

39
h-index

85541

71
g-index

167
all docs

167
docs citations

167
times ranked

7910
citing authors

#	ARTICLE	IF	CITATIONS
1	The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. <i>British Journal of Haematology</i> , 2022, 196, 488-506.	2.5	14
2	Alcohol and tobacco use and risk of multiple myeloma: A case-control study. <i>EJHaem</i> , 2022, 3, 109-120.	1.0	3
3	The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1001-1003.	2.4	1
4	Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. <i>Leukemia and Lymphoma</i> , 2022, 63, 2364-2374.	1.3	6
5	CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8069-TPS8069.	1.6	2
6	Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA. <i>Blood Advances</i> , 2022, 6, 5165-5170.	5.2	4
7	Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (<sc>MRDR</sc>). <i>British Journal of Haematology</i> , 2022, 198, 830-837.	2.5	8
8	A Wolf in Sheep's clothing: A case report series of oral manifestations of multiple myeloma. <i>Australian Dental Journal</i> , 2021, 66, 324-331.	1.5	6
9	Outcomes Following Extracorporeal Photopheresis for Chronic Lung Allograft Dysfunction Following Lung Transplantation: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2021, 53, 296-302.	0.6	8
10	Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2021, 62, 1271-1274.	1.3	1
11	Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study. <i>Mycoses</i> , 2021, 64, 30-34.	4.0	5
12	Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience. <i>Internal Medicine Journal</i> , 2021, 51, 280-283.	0.8	3
13	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
14	KRd: the new KiD in the French myeloma induction class. <i>Blood</i> , 2021, 138, 105-106.	1.4	0
15	Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. <i>Pathology</i> , 2021, 53, 385-399.	0.6	12
16	Paving the way to precision medicine in multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 323-327.	2.2	2
17	CAR-T cell therapy: practical guide to routine laboratory monitoring. <i>Pathology</i> , 2021, 53, 408-415.	0.6	10
18	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). <i>Bone Marrow Transplantation</i> , 2021, 56, 2533-2543.	2.4	7

#	ARTICLE	IF	CITATIONS
19	CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nature Communications, 2021, 12, 3236.	12.8	99
20	Myeloma natural killer cells are exhausted and have impaired regulation of activation. Haematologica, 2021, 106, 2522-2526.	3.5	8
21	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Molecular Cell, 2021, 81, 2183-2200.e13.	9.7	59
22	Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. British Journal of Haematology, 2021, 194, 120-131.	2.5	27
23	Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. European Journal of Haematology, 2021, 107, 497-499.	2.2	2
24	The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e510-e520.	0.4	12
25	Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 444-450.e3.	0.4	17
26	Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). Journal of Clinical Oncology, 2021, 39, 3602-3612.	1.6	44
27	Australia and New Zealand Transplant and Cellular Therapies <scp>COVID-19</scp> vaccination consensus position statement. Internal Medicine Journal, 2021, 51, 1321-1323.	0.8	6
28	Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. Blood Reviews, 2021, 49, 100810.	5.7	15
29	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. Future Oncology, 2021, 17, 4797-4812.	2.4	6
30	Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects. Cancers, 2021, 13, 4479.	3.7	2
31	Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma. Clinical and Translational Immunology, 2021, 10, e1235.	3.8	3
32	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia, 2021, 35, 562-572.	7.2	43
33	Assessing the Immune Tumour Microenvironment (iTME) Using Multiplex Immunofluorescence Histochemistry (mIHC) Demonstrates Close Proximity of Cytotoxic T-Cells to Plasma Cells (PC) in Patients with Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2021, 138, 4705-4705.	1.4	0
34	Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone. Blood, 2021, 138, 1633-1633.	1.4	1
35	The development of a home-based therapeutic platform for multiple myeloma. Expert Review of Hematology, 2021, , 1-7.	2.2	0
36	Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1172-1174.	2.4	4

#	ARTICLE	IF	CITATIONS
37	Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 2153.	4.8	16
38	Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma. <i>Expert Review of Hematology</i> , 2020, 13, 1201-1210.	2.2	11
39	Retinal ischemia due to extramedullary plasmacytomas of the orbit. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 447-449.	1.5	2
40	A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 73, e4269-e4277.	5.8	11
41	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1630-1642.	10.7	237
42	Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. <i>Cell Death and Differentiation</i> , 2020, 27, 2217-2233.	11.2	29
43	Levofloxacin prophylaxis in patients with myeloma. <i>Lancet Oncology</i> , The, 2020, 21, e67.	10.7	6
44	A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE [®] (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 28-29.	1.4	83
45	Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 14-15.	1.4	7
46	Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 42-43.	1.4	58
47	First in-human study of in vivo imaging of ex vivo labeled CAR T cells with dual PET-MR.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3557-3557.	1.6	2
48	Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8509-8509.	1.6	22
49	Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8511-8511.	1.6	11
50	Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8547-8547.	1.6	1
51	CO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS8551-TPS8551.	1.6	6
52	Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study. <i>Blood</i> , 2020, 136, 40-41.	1.4	1
53	Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , 2020, 136, 11-12.	1.4	2
54	The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). <i>Blood</i> , 2020, 136, 30-31.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
56	The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment. <i>Cancers</i> , 2019, 11, 928.	3.7	5
57	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	13.7	435
58	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. <i>Cancer Discovery</i> , 2019, 9, 1036-1049.	9.4	129
59	Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e415-e424.	0.4	13
60	Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3772-3775.	7.0	46
61	FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2471-2476.	1.3	7
62	Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with SA@zary syndrome. <i>Blood</i> , 2019, 134, 1346-1350.	1.4	29
63	Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists. <i>Internal Medicine Journal</i> , 2019, 49, 615-621.	0.8	6
64	Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. <i>Scientific Reports</i> , 2018, 8, 4159.	3.3	79
65	Considerations for pre@transfusion immunohaematology testing in patients receiving the anti@CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. <i>Internal Medicine Journal</i> , 2018, 48, 210-220.	0.8	31
66	A phase 1 clinical trial evaluating marizomib, pomalidomide and low@dose dexamethasone in relapsed and refractory multiple myeloma (<sc>NPI</sc>@0052@107): final study results. <i>British Journal of Haematology</i> , 2018, 180, 41-51.	2.5	62
67	Treatment of patients with Waldenstr@macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2017, 47, 35-49.	0.8	10
68	The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period. <i>Journal of Cancer Survivorship</i> , 2017, 11, 329-338.	2.9	25
69	Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. <i>British Journal of Haematology</i> , 2017, 177, 441-448.	2.5	21
70	Multiple myeloma of the spine. <i>Neuroradiology Journal</i> , 2017, 30, 259-268.	1.2	28
71	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. <i>Blood</i> , 2017, 129, 2882-2895.	1.4	74
72	Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients. <i>European Journal of Haematology</i> , 2017, 99, 423-430.	2.2	43

#	ARTICLE	IF	CITATIONS
73	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. <i>Internal Medicine Journal</i> , 2017, 47, 938-951.	0.8	19
74	Physical Activity Preferences for People Living With Multiple Myeloma. <i>Cancer Nursing</i> , 2017, 40, E1-E8.	1.5	18
75	The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers. <i>Supportive Care in Cancer</i> , 2017, 25, 3447-3456.	2.2	33
76	Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. <i>European Journal of Haematology</i> , 2017, 98, 149-153.	2.2	26
77	Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling. <i>Frontiers in Immunology</i> , 2017, 8, 1247.	4.8	10
78	Update and new approaches in the treatment of Castleman disease. <i>Journal of Blood Medicine</i> , 2016, Volume 7, 145-158.	1.7	79
79	Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results. <i>Clinical Cancer Research</i> , 2016, 22, 4559-4566.	7.0	56
80	Engraftment syndrome manifesting as acute brachial neuropathy following high-dose chemotherapy for management of plasma cell myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2942-2945.	1.3	4
81	Myeloma of the central nervous system – an ongoing conundrum!. <i>Leukemia and Lymphoma</i> , 2016, 57, 1505-1506.	1.3	3
82	Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2016, 67, 21-37.	2.8	49
83	Spontaneous onset and transplant models of the V λ *MYC mouse show immunological sequelae comparable to human multiple myeloma. <i>Journal of Translational Medicine</i> , 2016, 14, 259.	4.4	21
84	Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection. <i>British Journal of Haematology</i> , 2016, 173, 947-949.	2.5	2
85	Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. <i>British Journal of Haematology</i> , 2016, 174, 711-720.	2.5	44
86	T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. <i>Nature</i> , 2016, 538, 518-522.	27.8	159
87	Caregivers' information needs and their experiences of care during treatment are associated with elevated anxiety and depression: a cross-sectional study of the caregivers of renal cancer survivors. <i>Supportive Care in Cancer</i> , 2016, 24, 4177-4186.	2.2	34
88	Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies. <i>Leukemia and Lymphoma</i> , 2016, 57, 1719-1722.	1.3	7
89	Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms. <i>Epigenomics</i> , 2016, 8, 55-66.	2.1	35
90	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 975-975.	1.4	20

#	ARTICLE	IF	CITATIONS
91	A Multicentre Study Investigating the Pharmacokinetics and Pharmacodynamics of Busulphan When Combined with Melphalan As Conditioning in Adult Autologous Transplant Recipients. <i>Blood</i> , 2016, 128, 2190-2190.	1.4	0
92	Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment. <i>Blood</i> , 2016, 128, 5199-5199.	1.4	1
93	Myelosuppressive Therapies Significantly Increase Pro-Inflammatory Cytokines and Directly Cause Bone Loss. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 886-897.	2.8	35
94	Ceritinib in patients with advanced anaplastic lymphoma kinase-“rearranged anaplastic large-cell lymphoma. <i>Blood</i> , 2015, 126, 1257-1258.	1.4	40
95	Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma". <i>Haematologica</i> , 2015, 100, e379-e379.	3.5	4
96	Outcome of the Stryker® Trident “All-Poly”™ Constraint Acetabular Insert: A District General Hospital Experience. <i>HIP International</i> , 2015, 25, 557-562.	1.7	4
97	Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. <i>British Journal of Haematology</i> , 2015, 171, 100-108.	2.5	94
98	Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. <i>Supportive Care in Cancer</i> , 2015, 23, 1901-1906.	2.2	30
99	Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. <i>Haematologica</i> , 2015, 100, e28-e31.	3.5	62
100	The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit. <i>American Journal of Hematology</i> , 2015, 90, E86-91.	4.1	7
101	Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the <sc>M</sc>yeloma <sc>F</sc>oundation of <sc>A</sc>ustralia <sc>M</sc>edical and <sc>S</sc>cientific <sc>A</sc>dvisory <sc>G</sc>roup. <i>Internal Medicine Journal</i> , 2015, 45, 94-105.	0.8	13
102	Management of systemic <sc>AL</sc> amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 371-382.	0.8	19
103	Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1325-1336.	4.4	19
104	The utility and limitations of 18F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. <i>Leukemia and Lymphoma</i> , 2015, 56, 49-56.	1.3	16
105	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. <i>Blood</i> , 2015, 126, 3038-3038.	1.4	16
106	Plasmacytoma of the testis in a patient with relapsed and refractory multiple myeloma: Case report and review of the literature. <i>Urology Annals</i> , 2015, 7, 530.	0.6	9
107	Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors. <i>Blood</i> , 2015, 126, 5375-5375.	1.4	0
108	Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. <i>Blood Cancer Journal</i> , 2014, 4, e236-e236.	6.2	54

#	ARTICLE	IF	CITATIONS
109	Myeloma and pregnancy: strange bedfellows?. <i>Leukemia and Lymphoma</i> , 2014, 55, 966-968.	1.3	9
110	A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2014, 111, 1072-1079.	6.4	113
111	Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2014, 55, 1053-1060.	1.3	12
112	A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patients. <i>BMC Medicine</i> , 2014, 12, 39.	5.5	41
113	The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 291-296.	0.4	12
114	Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. <i>Bone Marrow Transplantation</i> , 2014, 49, 1056-1062.	2.4	11
115	Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy. <i>Annals of Hematology</i> , 2014, 93, 1193-1200.	1.8	18
116	Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection. <i>Blood Reviews</i> , 2014, 28, 75-86.	5.7	52
117	Low Uptake of Upfront Autologous Transplantation for Myeloma in a Jurisdiction With Universal Health Care Coverage: A Population-Based Patterns of Care Study in Australia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 61-67.	0.4	5
118	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. <i>Blood</i> , 2014, 124, 2190-2195.	1.4	108
119	Perceived benefits and barriers to exercise for recently treated patients with multiple myeloma: a qualitative study. <i>BMC Cancer</i> , 2013, 13, 319.	2.6	43
120	Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide. <i>Thrombosis Research</i> , 2013, 131, 514-520.	1.7	9
121	Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1465-1472.	1.3	13
122	A Risk-Adapted Protocol for Delayed Administration of Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 42-47.	0.4	3
123	Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. <i>Bone Marrow Transplantation</i> , 2013, 48, 351-356.	2.4	21
124	Systematic Review of Quality Improvement Interventions Directed at Cancer Specialists. <i>Journal of Clinical Oncology</i> , 2013, 31, 1583-1591.	1.6	12
125	A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease. <i>Transplant Infectious Disease</i> , 2013, 15, E134-8.	1.7	12
126	Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. <i>British Journal of Cancer</i> , 2013, 109, 312-317.	6.4	64

#	ARTICLE	IF	CITATIONS
127	Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. <i>Clinical and Experimental Immunology</i> , 2013, 175, 49-58.	2.6	35
128	Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. <i>Haematologica</i> , 2012, 97, 64-72.	3.5	109
129	Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2197-2203.	1.6	251
130	M(yeloma)IXing up T maintenance. <i>Blood</i> , 2012, 119, 1-2.	1.4	22
131	Peripheral Blood CD34+ Cell Enumeration as a Predictor of Apheresis Yield: An Analysis of More Than 1,000 Collections. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 763-772.	2.0	48
132	A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax [®]). <i>Epigenomics</i> , 2012, 4, 571-589.	2.1	39
133	Emergence of central nervous system myeloma in the era of novel agents. <i>Hematological Oncology</i> , 2012, 30, 170-174.	1.7	34
134	Complete remission of localised gastric plasmacytomas following definitive radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 328-331.	1.8	8
135	To validate: Is it so simple?. <i>Transfusion and Apheresis Science</i> , 2011, 45, 209-211.	1.0	0
136	Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. <i>Blood</i> , 2011, 117, 3658-3668.	1.4	128
137	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood</i> , 2011, 118, 6274-6283.	1.4	83
138	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. <i>Blood</i> , 2011, 117, 1605-1613.	1.4	152
139	Response: dexamethasone dose alters expression of NK activating receptors in vivo. <i>Blood</i> , 2011, 118, 6466-6468.	1.4	4
140	Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. <i>Bone Marrow Transplantation</i> , 2011, 46, 764-765.	2.4	18
141	Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study. <i>Blood</i> , 2011, 118, 1856-1856.	1.4	10
142	Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity. <i>Blood</i> , 2011, 118, 1862-1862.	1.4	9
143	A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML. <i>Blood</i> , 2011, 118, 3625-3625.	1.4	1
144	Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. <i>Gene Therapy</i> , 2010, 17, 678-686.	4.5	105

#	ARTICLE	IF	CITATIONS
145	Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. <i>Gene Therapy</i> , 2010, 17, 1105-1116.	4.5	38
146	Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. <i>Leukemia</i> , 2010, 24, 22-32.	7.2	505
147	Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. <i>Pharmaceuticals</i> , 2010, 3, 2674-2688.	3.8	7
148	Lessons Learned From an Unusual Presentation of CD3 ⁺ , CD56 ⁺ T-Cell Large Granular Lymphocyte Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, e498-e502.	1.6	1
149	Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy. <i>Leukemia and Lymphoma</i> , 2010, 51, 2299-2302.	1.3	15
150	Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia. <i>Emerging Infectious Diseases</i> , 2010, 16, 1068-1075.	4.3	108
151	Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial. <i>Blood</i> , 2010, 116, 1961-1961.	1.4	10
152	Clinical Studies of Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2009, 15, 3958-3969.	7.0	334
153	Predicting durable remissions following thalidomide therapy for relapsed myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 223-229.	1.3	9
154	In Vivo Antagonistic Effects of Dexamethasone On Lenalidomide-Induced NK Cell Activation.. <i>Blood</i> , 2009, 114, 1639-1639.	1.4	1
155	Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.. <i>Blood</i> , 2009, 114, 2693-2693.	1.4	2
156	Overcoming Histone Deacetylase Inhibitor Induced Thrombocytopenia Using a Thrombopoietin Mimetic.. <i>Blood</i> , 2009, 114, 2416-2416.	1.4	0
157	Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy. <i>Leukemia and Lymphoma</i> , 2008, 49, 2272-2283.	1.3	13
158	The potential of histone deacetylase inhibitors for the treatment of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 385-387.	1.3	14
159	The development of novel immunotherapeutic approaches in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 652-654.	1.3	3
160	Regulatory T Cells (Treg) Are Depressed in Patients with Relapsed/Refractory Multiple Myeloma (MM) and Increases towards Normal Range in Responding Patients Treated with Lenalidomide (LEN).. <i>Blood</i> , 2008, 112, 1696-1696.	1.4	19
161	The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantially Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study. <i>Blood</i> , 2008, 112, 3596-3596.	1.4	5
162	High Response Rates with the Combination of Bortezomib, Dexamethasone and the Pan-Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma in a Phase I/II Clinical Trial. <i>Blood</i> , 2008, 112, 3698-3698.	1.4	20

#	ARTICLE	IF	CITATIONS
163	Gene-Modified CD8+ T Cells Undergo Functional Polarization to Effector and Central Memory Cells in Response to Antigen Exposure.. Blood, 2008, 112, 1531-1531.	1.4	0
164	Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.. Blood, 2007, 110, 1167-1167.	1.4	9
165	Immunotherapy of multiple myeloma: the start of a long and tortuous journey. Expert Review of Anticancer Therapy, 2006, 6, 1769-1785.	2.4	22
166	Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 2005, 33, 1140-1146.	0.4	18
167	Erythrophagocytosis. British Journal of Haematology, 2001, 113, 2-2.	2.5	2